Home / Resource Library / Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Results of a phase I study investigating zanubrutinib for treatment of chronic lymphocytic leukemia.